Since 1996, physicians have maintained a one-size-fits-all approach to treating immune dysfunction in the ICU: patients receive fluids, antibiotics, and blood pressure medication. This process is inefficient for hospitals and patients alike.
ICU admissions account for 1/3 of all hospital admissions, and there are over 5 million ICU admissions each year in the U.S. Approximately 80% of these admissions are due to underlying immune dysfunction, resulting in over 500,000 deaths annually.
ICU stays are expensive – these stays account for half of total aggregated hospital charges, or $81.7 billion.
Current technology requires 4-6 hours to determine the level of cytokines in a patient’s blood. For many patients, this period of time could be the difference between life and death.
PreDxion Bio is building a better way.
MicroKineTM was developed to measure a patient’s specific, individual immune response by identifying up to 6 cytokine proteins – proteins that control and direct the body’s response to inflammation – from a single drop of blood in just 30 minutes.
This quick turnaround time allows physicians to precisely treat patients before it is too late, thereby benefiting the patient.
The quick turnaround time also allows hospitals to treat patients more efficiently. This creates a costs savings opportunity, and increases the number of patients a given hospital can treat.